Respiratory Endotherapy Devices

Global Respiratory Endotherapy Devices Market to Reach US$1.7 Billion by 2030

The global market for Respiratory Endotherapy Devices estimated at US$1.4 Billion in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Diagnostic Devices, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the Therapeutic Devices segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$383.3 Million While China is Forecast to Grow at 6.6% CAGR

The Respiratory Endotherapy Devices market in the U.S. is estimated at US$383.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$346.5 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Respiratory Endotherapy Devices Market - Key Trends & Drivers Summarized
Inside the Airway: How Technological Advancements Are Transforming Interventional Pulmonary Procedures

What Is Elevating the Role of Endotherapy in Managing Chronic and Acute Respiratory Disorders?
The respiratory endotherapy devices market is rapidly gaining prominence as pulmonology transitions toward less invasive, precision-guided interventions for the diagnosis and treatment of both chronic and acute airway disorders. Conditions such as chronic obstructive pulmonary disease (COPD), bronchial stenosis, central airway obstruction, and lung cancers often require therapeutic endoscopy involving dilation, stenting, or ablation of obstructed airways. These interventions are increasingly being performed using advanced endotherapy devices, including balloon dilators, electrosurgical probes, cryotherapy systems, and airway stents, which enable targeted treatment with minimal trauma to surrounding tissues.

The rising burden of respiratory diseases-exacerbated by urban pollution, smoking, aging populations, and post-COVID complications-has created an urgent need for technologies that provide relief without resorting to major surgery. Endotherapy offers several advantages in this regard, such as outpatient feasibility, shorter recovery time, and lower risk of complications. In the context of lung cancer, for instance, bronchoscopic interventions are being used not only for palliative decompression but also for delivering localized therapy such as photodynamic treatment or brachytherapy. These shifts are supported by improvements in imaging-guided navigation and miniaturized instrumentation that enhance procedural safety and diagnostic accuracy, allowing pulmonologists to access deeper lung segments with higher precision.

What Innovations in Instrumentation and Imaging Are Transforming Endotherapy Device Performance?
Technological innovation is reshaping the performance, design, and application of respiratory endotherapy devices. One of the major advancements is the development of steerable, single-use bronchoscopes that reduce cross-contamination risks while improving navigation in complex airway anatomies. These disposable devices, paired with real-time fluoroscopy or electromagnetic navigation systems, enable clinicians to deliver therapy to previously inaccessible lesions. Moreover, balloon dilation systems with adjustable inflation profiles now provide graduated pressure control, reducing the risk of airway trauma during dilation procedures.

Another significant trend is the miniaturization and integration of electrosurgical and cryoablation devices into bronchoscopic platforms. Cryoprobes, capable of precisely freezing abnormal tissue for biopsy or ablation, are now available in flexible formats suitable for peripheral lung procedures. Similarly, argon plasma coagulation (APC) and radiofrequency ablation (RFA) tools are being adapted for transbronchial use to control hemoptysis or debulk tumors. Advanced stent delivery systems-often preloaded, self-expanding, and customizable in length and diameter-are improving treatment outcomes in airway stenosis and post-surgical strictures. Furthermore, endotherapy devices are now being designed with embedded sensors for real-time feedback on temperature, pressure, and positioning, thereby minimizing human error and enhancing procedural reproducibility.

How Do Clinical Protocols and Regional Healthcare Infrastructure Shape Market Penetration?
The adoption of respiratory endotherapy devices is highly influenced by local clinical protocols, reimbursement frameworks, and the availability of interventional pulmonology infrastructure. In high-income regions such as the U.S., Germany, Japan, and South Korea, respiratory endotherapy is increasingly being adopted as standard-of-care in tertiary centers for both diagnostic and therapeutic purposes. Hospitals in these countries are equipped with advanced imaging modalities, integrated operating suites, and trained interventional pulmonologists who can utilize the full spectrum of devices. Reimbursement for minimally invasive procedures and post-acute respiratory care is also well established in these regions, further encouraging adoption.

In contrast, middle-income regions such as Southeast Asia, Eastern Europe, and Latin America are witnessing growing interest in respiratory endotherapy, but uptake is often constrained by cost considerations and limited technical expertise. Nevertheless, the expansion of public-private partnerships and telemedicine-based training platforms is helping to bridge the skills gap. In India, China, and Brazil, government and non-profit initiatives targeting early detection and management of respiratory diseases are spurring demand for cost-effective, locally adapted endotherapy solutions. Mobile bronchoscopy units and outpatient interventional programs are beginning to appear in urban hospitals, bringing endotherapy within reach of a broader patient demographic.

What Is Sustaining Long-Term Growth in the Respiratory Endotherapy Devices Market?
The growth in the respiratory endotherapy devices market is driven by several factors, including the increasing prevalence of chronic respiratory diseases, rising demand for minimally invasive interventions, and ongoing innovation in procedural tools. A major growth driver is the shift toward ambulatory care models and outpatient interventions. With healthcare systems under pressure to reduce inpatient costs and surgical complications, bronchoscopic endotherapy provides a viable alternative that aligns with the goals of value-based care. The demand for these procedures is further fueled by the rise in early diagnosis of respiratory and thoracic conditions, often detected through low-dose CT scans and AI-assisted radiology.

In addition, the expanding role of interventional pulmonology as a distinct subspecialty is creating a robust clinical base for the adoption of advanced endotherapy tools. Hospitals and training centers are investing in simulation labs, hybrid ORs, and AI-guided procedural planning systems to support a new generation of pulmonary specialists. From a technology standpoint, the ongoing convergence of robotics, imaging, and material science is unlocking possibilities such as autonomous navigation, precision drug delivery, and nanocoated stents with anti-inflammatory properties.

Finally, global health policy initiatives focusing on respiratory health-such as the WHO’s Global Action Plan for the Prevention and Control of NCDs-are creating a favorable policy environment for investment and innovation in this domain. With aging populations, rising urban morbidity, and the continuing threat of respiratory pandemics, the role of endotherapy in managing pulmonary health is set to grow substantially. Future devices are expected to become more affordable, personalized, and digitally connected, securing a long-term trajectory of growth for this high-impact medical segment.

SCOPE OF STUDY:

The report analyzes the Respiratory Endotherapy Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Device (Diagnostic Devices, Therapeutic Devices); Specialist (Hospitals Specialist, Diagnostic Centers Specialist, Ambulatory Surgery Centers Specialist); End-Use (Peripheral Vascular Intervention End-Use, Endovascular Interventions End-Use, Cardiac End-Use, Interventional Radiology End-Use, Venous End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Ambu
• Armstrong Medical
• Boston Scientific
• CONMED Corporation
• Cook Medical
• Drägerwerk
• Fisher & Paykel Healthcare
• Flexicare Medical
• Getinge
• Halyard Health (Avanos Medical)
• Hudson RCI
• Intersurgical
• Karl Storz
• Laerdal Medical
• Medtronic
• Olympus
• PENTAX Medical
• Philips (Philips Respironics)
• ResMed
• Teleflex

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more